Latest Insurance Coverage News

Aroa Biosurgery has completed its Symphony randomised controlled trial, demonstrating improved healing rates for diabetic foot ulcers compared to standard care. The preliminary results pave the way for clinical adoption and potential US reimbursement.

Straker Ltd announces a pivotal leadership shift with the appointment of David Sowerby and Indiver Nagpal as Co-CEOs, marking a new era focused on commercial expansion and AI innovation. Founder Grant Straker transitions to a strategic board role to steer the company’s AI future.

Neometals Ltd has resolved a longstanding legal dispute with a $1 million settlement, clearing the way to focus on advancing its Barrambie Gold Project and sustainable processing technologies.

FINEOS Corporation Holdings PLC reports a robust €27.8 million cash balance at the end of 2025, maintaining its FY25 revenue guidance despite seasonal cash flow dips and currency fluctuations.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Lumos Diagnostics has achieved a major milestone by securing 100% Medicare reimbursement recognition for its FebriDx test across all seven US Medicare Administrative Contractors, paving the way for broader adoption in the American healthcare system.

Income Asset Management reports a 34% rise in Q1 FY2026 revenue despite uncovering a $3 million fraud involving a former employee, maintaining positive EBITDA and strong client engagement.

ImpediMed secures expanded insurance reimbursement for its SOZO platform, now covering over 301 million US lives and enhancing early detection of breast cancer-related lymphedema.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.